BHCM
RIGL icon

Brevan Howard Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Brevan Howard Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,071
Closed -$353K – 2501
2026
Q1 		$353K Sell
13,071
-2,471
-16% -$83K ﹤0.01% 1521
2025
Q4 		$666K Buy
+15,542
New +$586K 0.01% 956
2024
Q1 		– Sell
-1,037
Closed -$15K – 1299
2023
Q4 		$15K Buy
+1,037
New +$10.6K ﹤0.01% 1006

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's RIGL Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 13,071 shares — an estimated $353K sold.

Brevan Howard Capital Management first reported a position in RIGL in Q4 2023 and held it in 3 quarters. The position peaked at $666K in Q4 2025. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 13,071 Rigel Pharmaceuticals shares in Q2 2026, an estimated $353K.
  • Brevan Howard Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Brevan Howard Capital Management's Rigel Pharmaceuticals position peaked at $666K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.